| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T576 |
0-94 |
Sentence |
denotes |
On the other hand, T. whipplei is a Gram-positive bacterium responsible for Whipple’s disease. |
| T577 |
95-249 |
Sentence |
denotes |
The natural niche of T. whipplei is the human intestine since, in the intestinal mucosa, the bacterium is taken by macrophages, where it replicates [147]. |
| T578 |
250-412 |
Sentence |
denotes |
This bacterial infection is primally characterized by digestive tract disorders such as diarrhea (75% of cases), malabsorption, and weight loss (80–90% of cases). |
| T579 |
413-524 |
Sentence |
denotes |
Joint disease may appear more than six years before the diagnosis and occur in more than 80% of patients [148]. |
| T580 |
525-630 |
Sentence |
denotes |
Furthermore, neurological and cardiac disorders can also be frequently associated with Whipple’s disease. |
| T581 |
631-791 |
Sentence |
denotes |
For years the standard treatment for T. whipplei has included a combination of trimethoprim and sulfamethoxazole; however, relapses were not uncommon [149,150]. |
| T582 |
792-1001 |
Sentence |
denotes |
Later, in vitro studies, demonstrated that trimethoprim was inactive on this bacterium [154], while sulfamethoxazole induced bacterial resistance, making the co-administration completely ineffective [154,156]. |
| T583 |
1002-1165 |
Sentence |
denotes |
Based on the good results of treating C. burnetii infections, it was decided to test in vitro the association DCX/HCQ on T. whipplei, obtaining good results [154]. |
| T584 |
1166-1255 |
Sentence |
denotes |
DCX/HCQ efficacy on T. whipplei diseases was demonstrated in a clinical trial dated 2014. |
| T585 |
1256-1473 |
Sentence |
denotes |
This study showed that the administration of 200 mg/day DCX and 600 mg/day HCQ to 13 patients results in better outcomes (0/13 failures) even after 1 year of treatment, compared to standard antibiotics regimens [155]. |
| T586 |
1474-1723 |
Sentence |
denotes |
To date, several case reports available in the literature supported a therapy consisting of a combination of HCQ (600 mg/day) and DCX (200 mg/day) for a lifetime or at least one year, followed by a maintenance dosage of DXC used alone [156,157,158]. |
| T587 |
1724-1895 |
Sentence |
denotes |
In some cases, prophylaxis of intravenous ceftriaxone (2g/day) for the first two weeks followed by HCQ/DXC for at least 12–18 months has been recommended [72,159,160,161]. |
